Other languages Anebulo Pharmaceuticals, Inc.

Equities

ANEB

US0345691036

Delayed Nasdaq Other stock markets 04:30:00 2024-05-20 pm EDT			5-day change	1st Jan Change
2.15 ^USD	-6.52%		-10.79%	-11.16%

Feb. 13	Anebulo Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	CI
2023	Anebulo Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Anebulo Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	Feb. 13
Anebulo Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	Nov. 14
Anebulo Pharmaceuticals, Inc. Appoints Richie Cunningham as CEO	23-10-06
Anebulo Pharmaceuticals, Inc. Appoints Bimal Shah to Its Board of Directors	23-10-06
Anebulo Pharmaceuticals, Inc. Appoints Daniel George as Principal Financial Officer and Principal Accounting Officer	23-09-29
Anebulo Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended June 30, 2023	23-09-20
Kronos Bio Appoints Sandra Gardiner as Interim Chief Financial Officer	23-09-18
Anebulo Pharmaceuticals, Inc. Announces Resignation of Sandra A. Gardiner as Principal Financial Officer and Principal Accounting Officer	23-09-05
Anebulo Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	23-05-11
Anebulo Pharmaceuticals Reports Positive Data from Trial of Cannabinoid Intoxication Treatment; Shares Jump	23-03-28
Anebulo Pharmaceuticals Announces Positive Complete Phase 2 Clinical Data Demonstrating Potential of Aneb-001 as A Treatment for Acute Cannabinoid Intoxication	23-03-28
Anebulo Pharmaceuticals Appoints Sandra Gardiner as Acting Chief Financial Officer	23-03-08
Anebulo Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	23-02-10
Anebulo Pharmaceuticals, Inc. Announces Completion of Dosing and Preliminary Data from Part B of its Phase 2 Study of ANEB-001 for Acute Cannabinoid Intoxication	23-01-09
Anebulo Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2022	22-11-10
Anebulo Pharmaceuticals, Inc. Appoints Nat Calloway as Class II Director	22-10-28
Anebulo Pharmaceuticals Signs Deal to Raise $6.6 Million in Private Placement	22-09-26
Sector Update: Health Care Stocks Mixed Premarket Monday	22-09-26
Anebulo Pharmaceuticals Says Acute Cannabinoid Intoxication Treatment Reduced Negative Effects of THC in Phase 2 Trial	22-09-26
Anebulo Pharmaceuticals, Inc. Announces Positive Interim Data for ANEB-001 from Part B of its Phase 2 Clinical Trial for Acute Cannabinoid Intoxication	22-09-26

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Anebulo Pharmaceuticals, Inc.

Equities

ANEB

US0345691036

Other languages

Filters